A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer

Trial Profile

A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 23 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2017.
    • 20 Apr 2016 Status changed from recruiting to discontinued.
    • 19 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top